Nancy Lurker - 26 Nov 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
26 Nov 2025
Transactions value $
-$10,465
Form type
4
Filing time
01 Dec 2025, 16:09:54 UTC
Previous filing
11 Jul 2025
Next filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lurker Nancy Director C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN /s/ Ron Honig, Attorney-in-Fact 01 Dec 2025 0001450485

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Sale -$2.99K -200 -0.09% $14.95 216K 26 Nov 2025 Direct F1
transaction EYPT Common Stock Sale -$7.48K -500 -0.23% $14.95 216K 28 Nov 2025 Direct F1
holding EYPT Common Stock 127K 26 Nov 2025 By Family Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.